Monoclonal antibody to human carcinomas

• US 5,242,824 A
• Filed: 11/29/1989
• Issued: 09/07/1993
• Est. Priority Date: 12/22/1988
• Status: Expired due to Fees

• Current Assignee: Oncogen Limited Partnership
• Original Assignee: Oncogen
• Inventors: Hellstrom, Ingegerd, Hellstrom, Karl E.
• Primary Examiner(s): Lacey, David L.
• Assistant Examiner(s): Feisee, Lila
• Application Number:
  US07/443,696
• Time in Patent Office: 1,378 Days
• Field of Search: 424/85.8, 424/85.91, 424/88, 530/387, 530/388, 530/388.8, 530/391.3, 530/387.1, 435/7, 435/172.2, 435/240.27
• US Class Current: 435/344
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/6851 the antibody targeting a determinant of a tumour cell
• CPC Class Codes: A61K 47/6877 the antibody being an immunoglobulin containing regions, domains or residues from different species
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/77 Internalization into the cell

Abstract

The present invention relates to a novel monoclonal antibody reactive with human carcinoma cells. More particularly, the antibody of the invention is a monoclonal antibody reactive with a glycolipid cell membrane antigen on the surface of human carcinomas. The antibody displays a high degree of selectivity for carcinoma cells, showing a low degree of reactivity with certain normal human cells and no detectable reactivity with other types of tumors such as lymphomas, sarcomas or melanomas. In addition, the antibody of the invention is capable of internalizing within the carcinoma cells to which it binds and is therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates.

Claims

1. Monoclonal antibody BR64 produced by the hybridoma having the identifying characteristics of HB 9895 as deposited with the ATCC.

3. An Fab, F(ab'"'"')₂ or Fv fragment of the monoclonal antibody of claim 1 or 2.

4. The monoclonal antibody of claim 1 or 2, wherein the antibody is conjugated to a label that produces a detectable signal.

5. The monoclonal antibody of claim 4, wherein the label is selected from the group consisting of a radiolabel, an enzyme, a chromophore or a fluorescer.

8. A class or subclass switch variant of the monoclonal antibody of claim 1.

2. Monoclonal antibody BR64 produced by the hybridoma having the identifying characteristics of HB 10292 as deposited with the ATCC.

6. Hybridoma HB 9895 as deposited with the ATCC.

7. Hybridoma HB 10292 as deposited with the ATCC.